See more : Alpine Summit Energy Partners, Inc. (ALPS-U.V) Income Statement Analysis – Financial Results
Complete financial analysis of Vyant Bio, Inc. (VYNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vyant Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Epsom Properties Limited (EPSOMPRO.BO) Income Statement Analysis – Financial Results
- Tectonic Metals Inc. (TETOF) Income Statement Analysis – Financial Results
- Agile Content, S.A. (AGIL.MC) Income Statement Analysis – Financial Results
- Future Market Networks Limited (FMNL.NS) Income Statement Analysis – Financial Results
- Titanium Transportation Group Inc. (TTNM.TO) Income Statement Analysis – Financial Results
Vyant Bio, Inc. (VYNT)
About Vyant Bio, Inc.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.00K | 1.15M | 867.00K | 7.31M | 27.47M | 29.12M | 27.05M | 18.04M | 10.20M | 6.61M | 4.30M | 3.02M | 2.52M | 1.67M |
| Cost of Revenue | 1.01M | 1.85M | 1.10M | 3.70M | 18.72M | 18.07M | 17.10M | 14.10M | 8.45M | 4.92M | 3.93M | 3.12M | 3.52M | 2.53M |
| Gross Profit | -342.00K | -699.00K | -234.00K | 3.60M | 8.75M | 11.05M | 9.95M | 3.94M | 1.75M | 1.69M | 372.57K | -98.00K | -994.61K | -865.93K |
| Gross Profit Ratio | -51.35% | -60.89% | -26.99% | 49.34% | 31.84% | 37.95% | 36.77% | 21.85% | 17.12% | 25.50% | 8.66% | -3.25% | -39.44% | -51.99% |
| Research & Development | 6.77M | 4.27M | 3.23M | 0.00 | 2.49M | 4.79M | 5.97M | 5.48M | 4.62M | 2.19M | 2.11M | 2.07M | 1.17M | 1.34M |
| General & Administrative | 0.00 | 0.00 | 6.60M | 5.17M | 19.18M | 19.89M | 16.03M | 14.57M | 12.37M | 6.12M | 4.50M | 4.44M | 3.45M | 1.84M |
| Selling & Marketing | 8.80M | 8.42M | 2.72M | 1.15M | 5.27M | 4.99M | 4.67M | 5.27M | 3.96M | 1.84M | 1.40M | 1.57M | 715.97K | 239.46K |
| SG&A | 8.80M | 8.42M | 2.72M | 6.32M | 24.45M | 24.88M | 20.70M | 19.84M | 16.33M | 7.96M | 5.90M | 6.01M | 4.16M | 2.08M |
| Other Expenses | 0.00 | 57.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.57M | 12.70M | 5.95M | 6.32M | 26.94M | 29.67M | 26.67M | 25.32M | 20.95M | 10.15M | 8.01M | 8.09M | 5.33M | 3.42M |
| Cost & Expenses | 16.58M | 14.54M | 7.05M | 10.02M | 45.66M | 47.74M | 43.77M | 39.42M | 29.41M | 15.07M | 11.94M | 11.20M | 8.84M | 5.95M |
| Interest Income | 0.00 | 0.00 | 0.00 | 108.00K | 21.00K | 63.00K | 23.00K | 49.00K | 73.80M | 29.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 93.00K | 0.00 | 535.00K | 1.44M | 2.12M | 2.13M | 454.00K | 344.00K | 472.82K | 2.39M | 4.70M | 1.31M | 792.42K | 2.09M |
| Depreciation & Amortization | 843.00K | 8.23M | 2.56M | 757.00K | 2.11M | 2.17M | 2.38M | 1.66M | 838.60K | 326.48K | 353.41K | 13.05K | 537.31K | 3.24K |
| EBITDA | -15.07M | -15.71M | -5.06M | -5.03M | -16.14M | -18.62M | -16.72M | -19.36M | -17.68M | -10.32M | -1.61M | -18.56M | -7.08M | -5.23M |
| EBITDA Ratio | -2,262.61% | -651.39% | -583.85% | -68.80% | -58.75% | -64.10% | -47.96% | -107.33% | -173.36% | -156.16% | -37.46% | -614.68% | -280.68% | -314.18% |
| Operating Income | -15.91M | -15.71M | -7.62M | -2.71M | -18.19M | -18.62M | -16.72M | -21.38M | -19.21M | -8.46M | -7.64M | -8.18M | -6.32M | -4.29M |
| Operating Income Ratio | -2,389.19% | -1,368.12% | -879.24% | -37.14% | -66.23% | -63.95% | -61.83% | -118.50% | -188.34% | -128.01% | -177.62% | -271.08% | -250.76% | -257.31% |
| Total Other Income/Expenses | 105.00K | -2.87M | -1.03M | -4.68M | -2.18M | -4.34M | 921.00K | 9.00K | 215.98K | -4.57M | 974.96K | -11.70M | -2.08M | -3.04M |
| Income Before Tax | -15.81M | -18.58M | -8.65M | -7.40M | -20.37M | -22.96M | -15.80M | -21.37M | -18.99M | -13.04M | -6.67M | -19.89M | -8.41M | -7.33M |
| Income Before Tax Ratio | -2,373.42% | -1,618.03% | -997.69% | -101.26% | -74.16% | -78.84% | -58.42% | -118.45% | -186.22% | -197.22% | -154.96% | -658.64% | -333.42% | -439.96% |
| Income Tax Expense | 6.88M | 27.52M | 546.00K | -512.00K | -59.00K | -2.08M | 1.38M | -1.18M | -2.35M | -663.90K | 5.68M | -10.39M | -1.29M | -950.49K |
| Net Income | -22.69M | -46.10M | -9.20M | -6.71M | -20.37M | -20.88M | -15.80M | -20.18M | -16.64M | -12.37M | -6.67M | -19.89M | -8.41M | -7.33M |
| Net Income Ratio | -3,406.91% | -4,015.24% | -1,060.67% | -91.83% | -74.16% | -71.70% | -58.42% | -111.88% | -163.18% | -187.18% | -154.96% | -658.64% | -333.42% | -439.96% |
| EPS | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -294.00 | -264.20 | -397.81 | -278.28 | -381.45 | -350.99 | -305.94 |
| EPS Diluted | -3.87 | -10.19 | -18.50 | -17.40 | -111.98 | -151.58 | -149.45 | -293.97 | -263.85 | -396.90 | -277.98 | -381.45 | -350.61 | -305.61 |
| Weighted Avg Shares Out | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.65K | 62.99K | 31.10K | 23.95K | 52.14K | 23.95K | 23.95K |
| Weighted Avg Shares Out (Dil) | 5.87M | 4.53M | 497.20K | 385.60K | 181.94K | 137.75K | 105.74K | 68.66K | 63.08K | 31.17K | 23.98K | 52.14K | 23.98K | 23.98K |
Vyant Bio to Present at BioNJ's 11th Annual BioPartnering Conference
CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics...
3 Short Squeeze Candidates In The Health Care Sector
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
New collaboration mitigates risk in drug d iscovery process with artificial intelligence and in vitro “avatar” clinical trials
Vyant Bio Announces Newly Appointed Board of Directors
CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for...
Source: https://incomestatements.info
Category: Stock Reports